Global Diabetes Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030

Global Diabetes Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030


Summary

Diabetes drugs are treatments for diabetes by lowering the sugar lower in the blood. Diabetes is a kind of disease with common symptoms such as frequent urination, increased thirst and weight loss. The most common drugs used are insulin and oral medications.

According to APO Research, The global Diabetes Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Diabetes Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Diabetes Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Diabetes Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Diabetes Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global manufacturers of Diabetes Drugs include Sanofi, AstraZeneca, Bayer, Biocon, Boehringer Ingelheim, Dongbao Pharmaceutical, Eli Lilly, Ganlee and Ginwa, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Diabetes Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Diabetes Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Diabetes Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Diabetes Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Diabetes Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Diabetes Drugs sales, projected growth trends, production technology, application and end-user industry.

Diabetes Drugs segment by Company

Sanofi
AstraZeneca
Bayer
Biocon
Boehringer Ingelheim
Dongbao Pharmaceutical
Eli Lilly
Ganlee
Ginwa
Guangzhou Baiyun Mountain
Hisun Pharmacy
Hua Dong
Huadong Medicine
Jumpcan Pharmacy
KELUN
Merck & Co.
MSD
North China Pharmaceutical Group Corporation
Novartis
Novo Nordisk
Sanofi
SHIJIAZHUANG YILING PHARMACEUTICAL
Takeda
Taloph
Tianan Pharmaceutical
Tonghua DongBao
Wanbang Biopharmaceuticals
Diabetes Drugs segment by Type

Insulin
DPP-4
GLP-1
SGLT-2
Diabetes Drugs segment by Application

Type 1 Diabetes
Type 2 Diabetes
Diabetes Drugs segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia

Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetes Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diabetes Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetes Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Diabetes Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2019-2030).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Diabetes Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Diabetes Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Diabetes Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report


1 Market Overview
1.1 Product Definition
1.2 Global Diabetes Drugs Market Size, 2019 VS 2023 VS 2030
1.3 Global Diabetes Drugs Market Size Estimates and Forecasts (2019-2030)
1.4 Global Diabetes Drugs Sales Estimates and Forecasts (2019-2030)
1.5 Global Diabetes Drugs Market Average Price (2019-2030)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Diabetes Drugs Market Dynamics
2.1 Diabetes Drugs Industry Trends
2.2 Diabetes Drugs Industry Drivers
2.3 Diabetes Drugs Industry Opportunities and Challenges
2.4 Diabetes Drugs Industry Restraints
3 Diabetes Drugs Market by Manufacturers
3.1 Global Diabetes Drugs Revenue by Manufacturers (2019-2024)
3.2 Global Diabetes Drugs Sales by Manufacturers (2019-2024)
3.3 Global Diabetes Drugs Average Sales Price by Manufacturers (2019-2024)
3.4 Global Diabetes Drugs Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
3.5 Global Diabetes Drugs Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Diabetes Drugs Manufacturers, Product Type & Application
3.7 Global Diabetes Drugs Manufacturers Commercialization Time
3.8 Market Competitive Analysis
3.8.1 Global Diabetes Drugs Market CR5 and HHI
3.8.2 Global Top 5 and 10 Diabetes Drugs Players Market Share by Revenue in 2023
3.8.3 2023 Diabetes Drugs Tier 1, Tier 2, and Tier 3
4 Diabetes Drugs Market by Type
4.1 Diabetes Drugs Type Introduction
4.1.1 Insulin
4.1.2 DPP-4
4.1.3 GLP-1
4.1.4 SGLT-2
4.2 Global Diabetes Drugs Sales by Type
4.2.1 Global Diabetes Drugs Sales by Type (2019 VS 2023 VS 2030)
4.2.2 Global Diabetes Drugs Sales by Type (2019-2030)
4.2.3 Global Diabetes Drugs Sales Market Share by Type (2019-2030)
4.3 Global Diabetes Drugs Revenue by Type
4.3.1 Global Diabetes Drugs Revenue by Type (2019 VS 2023 VS 2030)
4.3.2 Global Diabetes Drugs Revenue by Type (2019-2030)
4.3.3 Global Diabetes Drugs Revenue Market Share by Type (2019-2030)
5 Diabetes Drugs Market by Application
5.1 Diabetes Drugs Application Introduction
5.1.1 Type 1 Diabetes
5.1.2 Type 2 Diabetes
5.2 Global Diabetes Drugs Sales by Application
5.2.1 Global Diabetes Drugs Sales by Application (2019 VS 2023 VS 2030)
5.2.2 Global Diabetes Drugs Sales by Application (2019-2030)
5.2.3 Global Diabetes Drugs Sales Market Share by Application (2019-2030)
5.3 Global Diabetes Drugs Revenue by Application
5.3.1 Global Diabetes Drugs Revenue by Application (2019 VS 2023 VS 2030)
5.3.2 Global Diabetes Drugs Revenue by Application (2019-2030)
5.3.3 Global Diabetes Drugs Revenue Market Share by Application (2019-2030)
6 Global Diabetes Drugs Sales by Region
6.1 Global Diabetes Drugs Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Diabetes Drugs Sales by Region (2019-2030)
6.2.1 Global Diabetes Drugs Sales by Region (2019-2024)
6.2.2 Global Diabetes Drugs Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Diabetes Drugs Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.3.2 North America Diabetes Drugs Sales by Country (2019-2030)
6.3.3 U.S.
6.3.4 Canada
6.4 Europe
6.4.1 Europe Diabetes Drugs Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.4.2 Europe Diabetes Drugs Sales by Country (2019-2030)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Diabetes Drugs Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.5.2 Asia Pacific Diabetes Drugs Sales by Country (2019-2030)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 LAMEA
6.6.1 LAMEA Diabetes Drugs Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.6.2 LAMEA Diabetes Drugs Sales by Country (2019-2030)
6.6.3 Mexico
6.6.4 Brazil
6.6.5 Turkey
6.6.6 GCC Countries
7 Global Diabetes Drugs Revenue by Region
7.1 Global Diabetes Drugs Revenue by Region
7.1.1 Global Diabetes Drugs Revenue by Region: 2019 VS 2023 VS 2030
7.1.2 Global Diabetes Drugs Revenue by Region (2019-2024)
7.1.3 Global Diabetes Drugs Revenue by Region (2025-2030)
7.1.4 Global Diabetes Drugs Revenue Market Share by Region (2019-2030)
7.2 North America
7.2.1 North America Diabetes Drugs Revenue (2019-2030)
7.2.2 North America Diabetes Drugs Revenue Share by Country: 2019 VS 2023 VS 2030
7.3 Europe
7.3.1 Europe Diabetes Drugs Revenue (2019-2030)
7.3.2 Europe Diabetes Drugs Revenue Share by Country: 2019 VS 2023 VS 2030
7.4 Asia-Pacific
7.4.1 Asia-Pacific Diabetes Drugs Revenue (2019-2030)
7.4.2 Asia-Pacific Diabetes Drugs Revenue Share by Country: 2019 VS 2023 VS 2030
7.5 LAMEA
7.5.1 LAMEA Diabetes Drugs Revenue (2019-2030)
7.5.2 LAMEA Diabetes Drugs Revenue Share by Country: 2019 VS 2023 VS 2030
8 Company Profiles
8.1 Sanofi
8.1.1 Sanofi Comapny Information
8.1.2 Sanofi Business Overview
8.1.3 Sanofi Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.1.4 Sanofi Diabetes Drugs Product Portfolio
8.1.5 Sanofi Recent Developments
8.2 AstraZeneca
8.2.1 AstraZeneca Comapny Information
8.2.2 AstraZeneca Business Overview
8.2.3 AstraZeneca Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.2.4 AstraZeneca Diabetes Drugs Product Portfolio
8.2.5 AstraZeneca Recent Developments
8.3 Bayer
8.3.1 Bayer Comapny Information
8.3.2 Bayer Business Overview
8.3.3 Bayer Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.3.4 Bayer Diabetes Drugs Product Portfolio
8.3.5 Bayer Recent Developments
8.4 Biocon
8.4.1 Biocon Comapny Information
8.4.2 Biocon Business Overview
8.4.3 Biocon Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.4.4 Biocon Diabetes Drugs Product Portfolio
8.4.5 Biocon Recent Developments
8.5 Boehringer Ingelheim
8.5.1 Boehringer Ingelheim Comapny Information
8.5.2 Boehringer Ingelheim Business Overview
8.5.3 Boehringer Ingelheim Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.5.4 Boehringer Ingelheim Diabetes Drugs Product Portfolio
8.5.5 Boehringer Ingelheim Recent Developments
8.6 Dongbao Pharmaceutical
8.6.1 Dongbao Pharmaceutical Comapny Information
8.6.2 Dongbao Pharmaceutical Business Overview
8.6.3 Dongbao Pharmaceutical Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.6.4 Dongbao Pharmaceutical Diabetes Drugs Product Portfolio
8.6.5 Dongbao Pharmaceutical Recent Developments
8.7 Eli Lilly
8.7.1 Eli Lilly Comapny Information
8.7.2 Eli Lilly Business Overview
8.7.3 Eli Lilly Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.7.4 Eli Lilly Diabetes Drugs Product Portfolio
8.7.5 Eli Lilly Recent Developments
8.8 Ganlee
8.8.1 Ganlee Comapny Information
8.8.2 Ganlee Business Overview
8.8.3 Ganlee Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.8.4 Ganlee Diabetes Drugs Product Portfolio
8.8.5 Ganlee Recent Developments
8.9 Ginwa
8.9.1 Ginwa Comapny Information
8.9.2 Ginwa Business Overview
8.9.3 Ginwa Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.9.4 Ginwa Diabetes Drugs Product Portfolio
8.9.5 Ginwa Recent Developments
8.10 Guangzhou Baiyun Mountain
8.10.1 Guangzhou Baiyun Mountain Comapny Information
8.10.2 Guangzhou Baiyun Mountain Business Overview
8.10.3 Guangzhou Baiyun Mountain Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.10.4 Guangzhou Baiyun Mountain Diabetes Drugs Product Portfolio
8.10.5 Guangzhou Baiyun Mountain Recent Developments
8.11 Hisun Pharmacy
8.11.1 Hisun Pharmacy Comapny Information
8.11.2 Hisun Pharmacy Business Overview
8.11.3 Hisun Pharmacy Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.11.4 Hisun Pharmacy Diabetes Drugs Product Portfolio
8.11.5 Hisun Pharmacy Recent Developments
8.12 Hua Dong
8.12.1 Hua Dong Comapny Information
8.12.2 Hua Dong Business Overview
8.12.3 Hua Dong Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.12.4 Hua Dong Diabetes Drugs Product Portfolio
8.12.5 Hua Dong Recent Developments
8.13 Huadong Medicine
8.13.1 Huadong Medicine Comapny Information
8.13.2 Huadong Medicine Business Overview
8.13.3 Huadong Medicine Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.13.4 Huadong Medicine Diabetes Drugs Product Portfolio
8.13.5 Huadong Medicine Recent Developments
8.14 Jumpcan Pharmacy
8.14.1 Jumpcan Pharmacy Comapny Information
8.14.2 Jumpcan Pharmacy Business Overview
8.14.3 Jumpcan Pharmacy Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.14.4 Jumpcan Pharmacy Diabetes Drugs Product Portfolio
8.14.5 Jumpcan Pharmacy Recent Developments
8.15 KELUN
8.15.1 KELUN Comapny Information
8.15.2 KELUN Business Overview
8.15.3 KELUN Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.15.4 KELUN Diabetes Drugs Product Portfolio
8.15.5 KELUN Recent Developments
8.16 Merck & Co.
8.16.1 Merck & Co. Comapny Information
8.16.2 Merck & Co. Business Overview
8.16.3 Merck & Co. Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.16.4 Merck & Co. Diabetes Drugs Product Portfolio
8.16.5 Merck & Co. Recent Developments
8.17 MSD
8.17.1 MSD Comapny Information
8.17.2 MSD Business Overview
8.17.3 MSD Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.17.4 MSD Diabetes Drugs Product Portfolio
8.17.5 MSD Recent Developments
8.18 North China Pharmaceutical Group Corporation
8.18.1 North China Pharmaceutical Group Corporation Comapny Information
8.18.2 North China Pharmaceutical Group Corporation Business Overview
8.18.3 North China Pharmaceutical Group Corporation Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.18.4 North China Pharmaceutical Group Corporation Diabetes Drugs Product Portfolio
8.18.5 North China Pharmaceutical Group Corporation Recent Developments
8.19 Novartis
8.19.1 Novartis Comapny Information
8.19.2 Novartis Business Overview
8.19.3 Novartis Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.19.4 Novartis Diabetes Drugs Product Portfolio
8.19.5 Novartis Recent Developments
8.20 Novo Nordisk
8.20.1 Novo Nordisk Comapny Information
8.20.2 Novo Nordisk Business Overview
8.20.3 Novo Nordisk Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.20.4 Novo Nordisk Diabetes Drugs Product Portfolio
8.20.5 Novo Nordisk Recent Developments
8.21 Sanofi
8.21.1 Sanofi Comapny Information
8.21.2 Sanofi Business Overview
8.21.3 Sanofi Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.21.4 Sanofi Diabetes Drugs Product Portfolio
8.21.5 Sanofi Recent Developments
8.22 SHIJIAZHUANG YILING PHARMACEUTICAL
8.22.1 SHIJIAZHUANG YILING PHARMACEUTICAL Comapny Information
8.22.2 SHIJIAZHUANG YILING PHARMACEUTICAL Business Overview
8.22.3 SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.22.4 SHIJIAZHUANG YILING PHARMACEUTICAL Diabetes Drugs Product Portfolio
8.22.5 SHIJIAZHUANG YILING PHARMACEUTICAL Recent Developments
8.23 Takeda
8.23.1 Takeda Comapny Information
8.23.2 Takeda Business Overview
8.23.3 Takeda Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.23.4 Takeda Diabetes Drugs Product Portfolio
8.23.5 Takeda Recent Developments
8.24 Taloph
8.24.1 Taloph Comapny Information
8.24.2 Taloph Business Overview
8.24.3 Taloph Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.24.4 Taloph Diabetes Drugs Product Portfolio
8.24.5 Taloph Recent Developments
8.25 Tianan Pharmaceutical
8.25.1 Tianan Pharmaceutical Comapny Information
8.25.2 Tianan Pharmaceutical Business Overview
8.25.3 Tianan Pharmaceutical Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.25.4 Tianan Pharmaceutical Diabetes Drugs Product Portfolio
8.25.5 Tianan Pharmaceutical Recent Developments
8.26 Tonghua DongBao
8.26.1 Tonghua DongBao Comapny Information
8.26.2 Tonghua DongBao Business Overview
8.26.3 Tonghua DongBao Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.26.4 Tonghua DongBao Diabetes Drugs Product Portfolio
8.26.5 Tonghua DongBao Recent Developments
8.27 Wanbang Biopharmaceuticals
8.27.1 Wanbang Biopharmaceuticals Comapny Information
8.27.2 Wanbang Biopharmaceuticals Business Overview
8.27.3 Wanbang Biopharmaceuticals Diabetes Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
8.27.4 Wanbang Biopharmaceuticals Diabetes Drugs Product Portfolio
8.27.5 Wanbang Biopharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Diabetes Drugs Value Chain Analysis
9.1.1 Diabetes Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Diabetes Drugs Production Mode & Process
9.2 Diabetes Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Diabetes Drugs Distributors
9.2.3 Diabetes Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings